OVID (Ovid Therapeutics) LT-Debt-to-Total-Asset: 0.05 (As of Mar. 2026)

What is Ovid Therapeutics LT-Debt-to-Total-Asset?

Ovid Therapeutics OVID -2.42% 48 LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus rates OVID with a GF Score™ of 48/100 and a GF Value™ of $8.46 (Possible Value Trap). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ovid Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.05.

Ovid Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.16) to Mar. 2026 (0.05). It may suggest that Ovid Therapeutics is progressively becoming less dependent on debt to grow their business.

Ovid Therapeutics (NAS:OVID) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ovid Therapeutics LT-Debt-to-Total-Asset Related Terms

Ovid Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Ovid Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovid Therapeutics LT-Debt-to-Total-Asset Chart

Ovid Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.10

0.15

0.08

Ovid Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.16	0.19	0.08	0.05

48GF Score

Ovid Therapeutics Inc OVID

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ovid Therapeutics LT-Debt-to-Total-Asset Calculation

Ovid Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	11.986	/	150.934
	=	0.08

Ovid Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	11.611	/	225.628
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.05 mean?

Ovid Therapeutics (OVID) has a LT-Debt-to-Total-Asset of 0.05 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ovid Therapeutics and its competitors.

Is Ovid Therapeutics' LT-Debt-to-Total-Asset too high?

Ovid Therapeutics' current LT-Debt-to-Total-Asset is 0.05. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Ovid Therapeutics' LT-Debt-to-Total-Asset compare to ARTV and CCCC?

Ovid Therapeutics' LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ovid Therapeutics and its competitors. Ovid Therapeutics's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ovid Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $8.46, compared to a current price of $2.63 — trading 69% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. Ovid Therapeutics' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued. The current stock price of $2.63 is trading 69% below its estimated GF Value™ of $8.46. GuruFocus considers Ovid Therapeutics to be Possible Value Trap.

Key valuation signals for OVID:

LT-Debt-to-Total-Asset: 0.05
GF Value™: $8.46 vs. price of $2.63 (69% below fair value)
GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ovid Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ARTV CCCC RZLT CABA INDP OCGN STRO NGNE EDIT CBIO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 1OT:Germany

Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001

Website https://www.ovidrx.com

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

48GF Score

Get the complete analysis for OVID

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.63

Price

$8.46

GF Value

View OVID Analysis

See LT-Debt-to-Total-Asset data for all stocks →